{{Rsnum
|rsid=246240
|Gene=ABCC1
|Chromosome=16
|position=16025167
|Orientation=plus
|GMAF=0.2112
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ABCC1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 75.2 | 23.0 | 1.8
| HCB | 39.3 | 46.7 | 14.1
| JPT | 38.9 | 47.8 | 13.3
| YRI | 91.8 | 8.2 | 0.0
| ASW | 86.0 | 14.0 | 0.0
| CHB | 39.3 | 46.7 | 14.1
| CHD | 34.9 | 46.8 | 18.3
| GIH | 79.2 | 20.8 | 0.0
| LWK | 80.0 | 20.0 | 0.0
| MEX | 60.3 | 32.8 | 6.9
| MKK | 59.0 | 39.1 | 1.9
| TSI | 72.5 | 25.5 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs246240
|Name_s=
|Gene_s=ABCC1
|Feature=
|Evidence=PubMed ID:18256692
|Annotation=SNP is associated with development of hepatic or gastrointestinal toxicity to methotrexate in patients with psoriasis.
|Drugs=methotrexate
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161149206
}}

{{PharmGKB
|RSID=rs246240
|Name_s=
|Gene_s=ABCC1
|Feature=
|Evidence=PubMed ID:18256692
|Annotation=SNP is associated with the onset of toxicity to methotrexate in patients with psoriasis.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Psoriasis
|Curation Level=Curated
|PharmGKB Accession ID=PA161149204
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs246240
|overall_frequency_n=23
|overall_frequency_d=128
|overall_frequency=0.179688
|n_genomes=14
|n_genomes_annotated=0
|n_haplomes=18
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}